Detail Article

Informations générales (source: ClinicalTrials.gov)

Numéro NCT

NCT06317714 En recrutement

Titre

Non-interventional and Longitudinal Study to Evaluate a List of Anticancer Drugs Under Real Conditions of Use and Measure the Quality of Life of Patients Treated at Rafaël Institute (THERAPINNOV)

Type

Observational [Patient Registry]

Pathologie

Phase

Promoteur

Institut Rafael (Voir sur ClinicalTrials)

Date de début

mars 2024

Date de fin

mars 2027

Dernière mise à jour

02 octobre 2024

Résumé

Currently, aspects related to the effects of anticancer treatments and the quality of life of patients and their needs are still poorly documented at the Rafael Institute. Thus this study will meet a dual objective: (1) the establishment of a registry to collect data on the safety and effectiveness of innovative and expensive anticancer drugs when administered in real life and (2) a measurement quantitative quality of life of patients treated with these drugs.

Détail

Voir le détail In France, the promotion of more patient-centered medicine is among the priorities identified by the High Authority for Health in its 2024 strategic project. The patient-centered approach is based on a partnership relationship with the patient, their loved ones, and the healthcare professional or a multi-professional team to built together the best option of care. In this approach, the Rafael Institute was created with the objective of caring for people and not simply pathologies. Initiated around the problem of cancer and the harmful effects of its treatments, the Rafaël Institute offers personalisation of care and continuity of care over time by providing monitoring and support to the patient by a multi-professional and multidisciplinary team. Thus, maintaining quality of life constitutes one of the objectives of the therapeutic management of patients with cancer. Although modern oncological treatments have today enabled real advances on the biomedical level, they often have side effects that must be taken into account for the overall assessment and management of patients. Although most anticancer therapies have a negative impact on the patient's quality of life, this does not always reflect the occurrence of toxicity. Since the 1990s, quality of life has been strongly associated with survival. Patients with high overall quality of life live significantly longer than patients with low overall quality of life. The relationship between symptoms, their intensity and quality of life is essential to study to understand the perceived impact of treatments and optimize their use in daily practice. The effects of treatment and quality of life can be assessed precisely and reliably using standardized and validated self-questionnaires. Completed by patients, they make it possible to measure the qualitative aspects directly linked to their health and to take into account their subjective perception of their state of health. Fermer le détail

Etablissements

Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Institute Rafaël - 92300 - Levallois Perret - Institut Rafael - France	Alain Toledano	En recrutement		Contact (sur clinicalTrials)

Critères

Genre

Tous

Nombre d'inclusion

Critère d'inclusion

Inclusion Criteria:

- Age equal to or greater than 18 years (adult)

- Patients treated with an anticancer drug included in the list of
innovative/expensive therapies (protocol appendix)

- Patients benefiting from non-pharmacological treatment at the Rafael Institute

- Who understands the French language

Critère de non inclusion

- < 18 years old

- Patient deprived of liberty, under guardianship or unable to give consent

NCT06317714 - Non-interventional and Longitudinal Study to Evaluate a List of Anticancer Drugs Under Real Conditions of Use and Measure the Quality of Life of Patients Treated at Rafaël Institute (THERAPINNOV)

Informations générales
Etablissements
Critères
Accès à la fiche NCT

Retour en haut